Company: BSX
Filing Date: 2025-08-01
Form Type: 10-Q
Source: 0000885725-25-000041
Chunk: 152

Company: BOSTON SCIENTIFIC CORP
Filing Date: 2025-08-01
Form: 10-Q
Item: Part I, Item 8
Chunk 152
---
.22 per diluted share. Our reported results for the second quarter of 2024 included certain charges and/or credits totaling $589 million (after-tax), or $0.40 per diluted share. Excluding these items, adjusted net income attributable to Boston Scientific common stockholders3 was $914 million, or $0.62 per diluted share.

1Operational net sales growth excludes the impact of foreign currency fluctuations.

2Organic net sales growth excludes the impact of foreign currency fluctuations and net sales attributable to certain acquisitions and divestitures for which there are less than a full period of comparable net sales.

3Adjusted measures, including operational and organic net sales growth and adjusted net income attributable to Boston Scientific common stockholders, exclude certain items required by generally accepted accounting principles in the United States (GAAP), are not prepared in accordance with GAAP and should not be considered in isolation from, or as a replacement for, the most directly comparable GAAP measure. Refer to Additional Information for a discussion of management’s use of these non-GAAP financial measures. 

39

The following is a reconciliation of our results of operations prepared in accordance with GAAP to those adjusted results considered by management. Refer to Quarterly Results and Business Overview and Additional Information for a discussion of these reconciling items:

 Three Months Ended June 30, 2025(in millions, except per share data)Income (Loss) Before Income TaxesIncome Tax Expense (Benefit)Net Income (Loss)Net Income (Loss) Attributable to Noncontrolling InterestsNet Income (Loss) Attributable to Boston Scientific Common StockholdersImpact per ShareReported$941 $146 $795 $(2)$797 $0.53 Non-GAAP adjustments:Amortization expense225 32 193 2 191 0.13 Goodwill and other intangible asset impairment charges46 837—370.02 Acquisition/divestiture-related net charges (credits)(92)0(92)—(92)(0.06)Restructuring and restructuring-related net charges (credits)161 19142—1420.10 Investment portfolio net losses (gains) and impairments(2)0(2)—(2)(0.00)European Union (EU) Medical device regulation (MDR) implementation costs10 19—90.01 Deferred tax expenses (benefits)— (45)45—450.03 Discrete tax items— (0)0—00.00